Rani Therapeutics Holdings (RANI) Cash from Financing Activities (2020 - 2026)

Rani Therapeutics Holdings' Cash from Financing Activities history runs 7 years deep, the most recent figure standing at -$27000.0 for Q1 2026.

• On a quarterly basis, Cash from Financing Activities rose 99.28% year-over-year to -$27000.0 in Q1 2026; TTM through Mar 2026 was $44.0 million, a 352.11% increase from a year earlier, with the FY2025 full-year figure at $40.3 million, up 196.65% from the prior year.
• Cash from Financing Activities retreated to -$27000.0 in Q1 2026 per RANI's latest filing, from $44.9 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $44.9 million in Q4 2025 and bottomed at -$3.7 million in Q1 2025.
• The 5-year median for Cash from Financing Activities is $108500.0 (2023), against an average of $5.2 million.
• Across the five-year window, Cash from Financing Activities soared 15622.45% in 2024 and sank 3183.47% in 2025, its largest moves.
• Year by year, Cash from Financing Activities stood at $14.9 million in 2022, then plunged by 99.35% to $96000.0 in 2023, then soared by 5753.12% to $5.6 million in 2024, then jumped by 698.22% to $44.9 million in 2025, then plunged by 100.06% to -$27000.0 in 2026.
• Per Business Quant, the three latest RANI Cash from Financing Activities figures stand at -$27000.0 (Q1 2026), $44.9 million (Q4 2025), and -$1.0 million (Q3 2025).